Zydus has announced the successful completion of a routine USFDA surveillance inspection at its Topical Manufacturing facility in Changodar, Ahmedabad. Conducted from February 10th to 14th, 2025, the inspection concluded with zero observations, reflecting the company’s commitment to quality and compliance.
In the exchange filing, the company shared, “We wish to inform that the USFDA conducted a routine surveillance inspection at the group’s Topical Manufacturing site situated at Changodar in Ahmedabad. The inspection was conducted from February 10th to 14th, 2025. The inspection concluded with NIL observations.”
Zydus Lifesciences Q3 FY25 Financial Results
On February 5, Zydus Lifesciences Limited delivered impressive financial results for Q3 FY25, showcasing strong revenue growth and profitability. The company’s consolidated revenue from operations surged 16.78% YoY to ₹5,269.1 crore, compared to ₹4,505.2 crore in Q3 FY24.
Despite a 14.52% rise in total expenses to ₹4,142.5 crore, Zydus achieved a remarkable 46.78% YoY increase in Profit Before Tax (PBT), reaching ₹1,044.6 crore. The company’s net profit grew 29.6% YoY to ₹1,023.8 crore, fueled by operational efficiency and cost optimization.
A key highlight was the significant forex gain of ₹183 crore, up from ₹21 crore in the previous year, reflecting strong currency management. EBITDA surged 25.85% YoY to ₹1,387 crore, with an EBITDA margin expansion to 26.3% from 24.5% YoY.
